[go: up one dir, main page]

WO2021156184A1 - New formulation of a plant extract - Google Patents

New formulation of a plant extract Download PDF

Info

Publication number
WO2021156184A1
WO2021156184A1 PCT/EP2021/052268 EP2021052268W WO2021156184A1 WO 2021156184 A1 WO2021156184 A1 WO 2021156184A1 EP 2021052268 W EP2021052268 W EP 2021052268W WO 2021156184 A1 WO2021156184 A1 WO 2021156184A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
powderous
formulation according
present
maltodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/052268
Other languages
French (fr)
Inventor
Yi-Ting MAH
Hiroyuki Sasaki
Diptee Kshitij THAKUR
Min Ling Marlene TSAO
Chi-Ming YIP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG10202001110VA external-priority patent/SG10202001110VA/en
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of WO2021156184A1 publication Critical patent/WO2021156184A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a new formulation of a specific plant extract.
  • the specific plant extract is the leaf extract of the white mulberry tree.
  • White mulberry (Latin name is Morus alba), is a fast-growing, small to medium-sized mul berry tree which grows to 10-20 m tall.
  • the species is originally native to northern China, and is now widely cultivated and natu ralized in many other countries (such as i.e. United States, Mexico, Australia, Kyrgyzstan, Argentina, Turkey, Iran, etc.)/
  • Mulberry leaves have a long history of medicinal use in Asian countries, in particular China.
  • phytochemists have isolated a number of imino sugar constituents from mulberry leaves, such as 1 -deoxynojirimycin (DNJ), fagomine, and N- methyl-DNJ.
  • DNJ 1 -deoxynojirimycin
  • fagomine fagomine
  • N- methyl-DNJ The chemical structures of the imino sugars are similar to that of monosaccharides, being mostly polyhydroxyl heterocyclics with a 5 to 6-membered ring.
  • white mulberry leaf extracts such as i.e. Reducose ® 1% and Reducose ® 5% from DSM Nutritional Products Ltd.
  • the problem of the white mulberry leaf extracts is the strong hygroscopicity. This has for example a negative effect on the flowability property of the formulation.
  • the flowability is a very important property of a powderous formulation.
  • the present invention relates to a powderous formulation (PF) comprising
  • the powderous formulation according to the present invention comprises at least 55wt-% of maltodextrin.
  • the present invention relates to a powderous formulation (PF1), which is pow derous formulation (PF), wherein the powderous formulation comprises at least 55 wt-%, based on the total weight of the powderous formulation of maltodextrin.
  • the formulation according to the present invention comprises up to 99 wt-% of maltodextrin.
  • the present invention relates to a powderous formulation (PF2), which is pow derous formulation (PF) or (PF1), wherein the powderous formulation comprises up to 99 wt-%, based on the total weight of the powderous formulation of maltodextrin.
  • the present invention relates to a powderous formulation (PF3), which powder ous formulation (PF), (PF1) or (PF3) comprising 50 to 99 wt-%, based on the total weight of the powderous formulation of maltodextrin.
  • the formulation according to the present invention can optionally comprise further ingreists, which could added to such formulation, but which are not essential for the excellent property of the powderous formulation according to the present invention.
  • ingredi ents can be vitamins, minerals, fillers, dyestuff, flavours, fibers, etc.
  • the present invention relates to a powderous formulation (PF4) comprising
  • composition according to the present invention can be used as such (as dietary sup plement, food supplement, feed, feed supplement or any further possible use).
  • the formulation according to the present invention can also be used to be formulated into other product forms. This means the powderous formulation according to the present in vention can serve as a premix.
  • the present invention also related to the use of a powderous formulation (PF5), (PF1), (PF2), (PF3) or (P4) as dietary supplement, food supplement, feed, feed supple ment.
  • the present invention also related to the use of a powderous formulation (PF5’), (PF1), (PF2), (PF3) or (P4) as premix.
  • the formulation according to the present invention can be produced according to com monly known methods.
  • the powderous formulation according to the present invention is single particle. This means that all components (i), (ii) and (iii) are part of one particle.
  • the size and the shape of such a particle is not essential to the invention. It should be in a suitable form to be used for the desired use.
  • the powderous formulation according to the present invention is a mixture of more than one specific particle. This means that components (i), (ii) and (iii) are all different particles, which are then mixed together.
  • ingredients of the powderous formulation according to the present invention are mixed the sequence of mixing is no essential. All ingredients can be added all at once and the mixed or they can be added one after the other, or in any possible combination.
  • a preferred method is that the leaf extract of the white mulberry tree is produced (usually by spray drying and the mixed and then mix it with component (ii) and optionally with (iii)/ As stated the sequence of mixing is not essential for the invention. It is also possible to use commercially available leaf extract of the white mulberry tree such as Reducose ® 1% or Reducose® 5% or a mixture of them, (these products are available from DSM Nutritional Products Ltd) and mix it with Maltodextrin and optionally and other ingredients (component (iii).
  • the mixing time was 5 min and the temperature was 20°C (humidity: 50% RH).
  • the so obtained powderous formulation was then tested in view of flowability. This was done by determining the desorption as well as the adsorption. This was done by the Dynamic Vapor Sorption (DVS) test Performed using Aqualab Vapor Sorption Analyzer.
  • DVD Dynamic Vapor Sorption
  • the DVS method for static or equilibrium isotherms consists of tracking sample weight change as the sample is exposed to deferent controlled humidities.
  • the sample is held at each humidity for a preset time interval or until a steady state weight change is achieved, the goal being to achieve equilibrium between the sample water ac tivity and the controlled humidity.
  • eight change versus time data is recorded allowing for determining kinetics of sorption for each humidity level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a new formulation of a specific plant extract.

Description

NEW FORMULATION OF A PLANT EXTRACT
The present invention relates to a new formulation of a specific plant extract.
The specific plant extract is the leaf extract of the white mulberry tree.
White mulberry (Latin name is Morus alba), is a fast-growing, small to medium-sized mul berry tree which grows to 10-20 m tall.
The species is originally native to northern China, and is now widely cultivated and natu ralized in many other countries (such as i.e. United States, Mexico, Australia, Kyrgyzstan, Argentina, Turkey, Iran, etc.)/
Mulberry leaves have a long history of medicinal use in Asian countries, in particular China. In recent years, phytochemists have isolated a number of imino sugar constituents from mulberry leaves, such as 1 -deoxynojirimycin (DNJ), fagomine, and N- methyl-DNJ. The chemical structures of the imino sugars are similar to that of monosaccharides, being mostly polyhydroxyl heterocyclics with a 5 to 6-membered ring.
It has been shown that the imino sugar constituents from mulberry leaves exhibit certain inhibitory activity on oglucosidase I and II, among which DNJ showed the strongest activ ity. Further pharmacological experiments revealed that DNJ acted on melanocyte inhibit ing the maturing process of TYR, which resulted in the reduction of melanin production. (Genji Imokawa, Analysis of Carbohydrate Properties Essential for Melanogenesis in TYRs of Cultured Malignant Melanoma Cells by Differential Carbohydrate Processing In hibition. The Journal of Investigative dermatology, 1990,
95(1 ):39-49; Ju Young Park, hyunjung Choi, Jae Sung hwang, Junoh Kim, Ih-Seop Chang, Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sen- sitive liposomes into HM3KO melanoma cells, Journal of Cosmetic Science, 2008, 59: ISO- ISO.)
There many commercially available supplements (in various forms) containing white mul berry leaf extract. The white mulberry leaf extract is known
• to support healthy sugar levels and blood circulation
• to improve the overall digestive health
• to lower glucose levels and stabilizes blood sugar in the body by managing appe tite and reducing cravings
• to support healthy weight loss by helping to control your appetite, sugar cravings and its absorption.
To produce such supplements, it is necessary to provide a formulation of the white mul berry leaf extract, which is then incorporated into the desired end market product.
There are also commercially available formulations of white mulberry leaf extracts (such as i.e. Reducose® 1% and Reducose® 5% from DSM Nutritional Products Ltd).
Due to the importance of the leaf extract of the white mulberry, there is always a need for improved formulations of such an extract.
The problem of the white mulberry leaf extracts is the strong hygroscopicity. This has for example a negative effect on the flowability property of the formulation. The flowability is a very important property of a powderous formulation.
It was now found that the when the leaf extract of the white mulberry is formulated with a specific (high amount) of maltodextrin (and optionally other ingredients) the flowability of the obtained powder is improved significantly.
Therefore the present invention relates to a powderous formulation (PF) comprising
(i) a leaf extract of the white mulberry tree and
(ii) at least 50 weight-% (wt-%), based on the total weight of the powderous for mulation of maltodextrin.
It is clear that all the percentages always add up to 100. Surprisingly such a powderous formulation has excellent flowability properties.
Preferably the powderous formulation according to the present invention comprises at least 55wt-% of maltodextrin.
Therefore the present invention relates to a powderous formulation (PF1), which is pow derous formulation (PF), wherein the powderous formulation comprises at least 55 wt-%, based on the total weight of the powderous formulation of maltodextrin.
Preferably, the formulation according to the present invention comprises up to 99 wt-% of maltodextrin.
Therefore the present invention relates to a powderous formulation (PF2), which is pow derous formulation (PF) or (PF1), wherein the powderous formulation comprises up to 99 wt-%, based on the total weight of the powderous formulation of maltodextrin.
Therefore the present invention relates to a powderous formulation (PF3), which powder ous formulation (PF), (PF1) or (PF3) comprising 50 to 99 wt-%, based on the total weight of the powderous formulation of maltodextrin.
The formulation according to the present invention can optionally comprise further ingre dients, which could added to such formulation, but which are not essential for the excellent property of the powderous formulation according to the present invention. Such ingredi ents can be vitamins, minerals, fillers, dyestuff, flavours, fibers, etc.
Therefore the present invention relates to a powderous formulation (PF4) comprising
(i) a leaf extract of the white mulberry tree and
(ii) at least 50 wt-%, based on the total weight of the formulation of maltodextrin and
(iii) at least one further ingredient. The formulation according to the present invention can be used as such (as dietary sup plement, food supplement, feed, feed supplement or any further possible use).
The formulation according to the present invention can also be used to be formulated into other product forms. This means the powderous formulation according to the present in vention can serve as a premix.
Therefore the present invention also related to the use of a powderous formulation (PF5), (PF1), (PF2), (PF3) or (P4) as dietary supplement, food supplement, feed, feed supple ment.
Therefore the present invention also related to the use of a powderous formulation (PF5’), (PF1), (PF2), (PF3) or (P4) as premix.
The formulation according to the present invention can be produced according to com monly known methods.
It is possible that the powderous formulation according to the present invention is single particle. This means that all components (i), (ii) and (iii) are part of one particle. The size and the shape of such a particle is not essential to the invention. It should be in a suitable form to be used for the desired use.
It is possible that the powderous formulation according to the present invention is a mixture of more than one specific particle. This means that components (i), (ii) and (iii) are all different particles, which are then mixed together.
This means that components (i) and (ii) form one particle, which is mixed with (iii) or any other variation thereof.
When the ingredients of the powderous formulation according to the present invention are mixed the sequence of mixing is no essential. All ingredients can be added all at once and the mixed or they can be added one after the other, or in any possible combination.
A preferred method is that the leaf extract of the white mulberry tree is produced (usually by spray drying and the mixed and then mix it with component (ii) and optionally with (iii)/ As stated the sequence of mixing is not essential for the invention. It is also possible to use commercially available leaf extract of the white mulberry tree such as Reducose ® 1% or Reducose® 5% or a mixture of them, (these products are available from DSM Nutritional Products Ltd) and mix it with Maltodextrin and optionally and other ingredients (component (iii).
The following examples serve to illustrate the invention.
Examples Example 1
200 g of Reducose 5% (from DSM Nutritional Products Ltd) and 1800 g Maltodextrin were mixed in a double action tumbler (sieve: 0.5 mm).
The mixing time was 5 min and the temperature was 20°C (humidity: 50% RH).
The so obtained powderous formulation was then tested in view of flowability. This was done by determining the desorption as well as the adsorption. This was done by the Dynamic Vapor Sorption (DVS) test Performed using Aqualab Vapor Sorption Analyzer.
The DVS method for static or equilibrium isotherms consists of tracking sample weight change as the sample is exposed to deferent controlled humidities.
The sample is held at each humidity for a preset time interval or until a steady state weight change is achieved, the goal being to achieve equilibrium between the sample water ac tivity and the controlled humidity. eight change versus time data is recorded allowing for determining kinetics of sorption for each humidity level.
Effective Relative Humidity = aw X 100 (i.e 0.1 aw = 10% RH)
In the following table the results can be seen
Figure imgf000007_0001

Claims

Claims
1. Powderous formulation comprising
(i) a leaf extract of the white mulberry tree and
(ii) at least 50 wt-%, based on the total weight of the formulation, of maltodex- trin.
2. Powerdous formulation according to claim 1 , which comprises at least 55wt-%, based on the total weight of the formulation, of maltodextrin.
3. Powerdous formulation according to claim 1 or 2, which comprises up to 99 wt-%, based on the total weight of the formulation, of maltodextrin.
4. Powerdous formulation according to any of the preceding claims, wherein the formu lation comprises further ingredients.
5. Use of a powderous formulation according to any of claims 1 - 4 as dietary supple ment, food supplement, feed, feed supplement or any further possible use).
6. Use of a powderous formulation according to any of claims 1 - 4 as a premix.
7. Process of production of a powderous formulation according to any of claims 1 - 4 wherein the components (i) and (ii) and optionally (iii) are mixed.
PCT/EP2021/052268 2020-02-07 2021-02-01 New formulation of a plant extract Ceased WO2021156184A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SG10202001110VA SG10202001110VA (en) 2020-02-07 2020-02-07 New Formulation Of A Plant Extract
SG10202001110V 2020-02-07
CH7562020 2020-06-23
CH00756/20 2020-06-23

Publications (1)

Publication Number Publication Date
WO2021156184A1 true WO2021156184A1 (en) 2021-08-12

Family

ID=74595256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/052268 Ceased WO2021156184A1 (en) 2020-02-07 2021-02-01 New formulation of a plant extract

Country Status (2)

Country Link
TW (1) TW202139863A (en)
WO (1) WO2021156184A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165856A1 (en) * 2022-03-02 2023-09-07 Société des Produits Nestlé S.A. Use of a composition for managing postprandial glucose response and associated disorders
GR1011012B (en) * 2024-05-21 2025-07-23 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε. Με Το Διακριτικο Τιτλο "Uni-Pharma A.B.E.E.", Berry extract-based cardioprotection composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618527A (en) * 1992-09-30 1997-04-08 Ascent Pediatrics Inc. Calcium polycarbophil sprinkle
WO2007040377A1 (en) * 2005-10-05 2007-04-12 Angiolab., Inc. Antiobesity composition
KR20180063390A (en) * 2016-11-25 2018-06-12 부안군(관리부서: 부안군 농업기술센터) Method for Preparing Mulberry Leaf Extracts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618527A (en) * 1992-09-30 1997-04-08 Ascent Pediatrics Inc. Calcium polycarbophil sprinkle
WO2007040377A1 (en) * 2005-10-05 2007-04-12 Angiolab., Inc. Antiobesity composition
KR20180063390A (en) * 2016-11-25 2018-06-12 부안군(관리부서: 부안군 농업기술센터) Method for Preparing Mulberry Leaf Extracts

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GENJI IMOKAWA: "Analysis of Carbohydrate Properties Essential for Melanogenesis in TYRs of Cultured Malignant Melanoma Cells by Differential Carbohydrate Processing Inhibition", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 95, no. 1, 1990, pages 39 - 49
JU YOUNG PARKHYUNJUNG CHOIJAE SUNG HWANGJUNOH KIMIH-SEOP CHANG: "Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells", JOURNAL OF COSMETIC SCIENCE, vol. 59, 2008, pages 139 - 150
TCHABO WILLIAM ET AL: "Process Analysis of Mulberry (Morus alba) Leaf Extract Encapsulation: Effects of Spray Drying Conditions on Bioactive Encapsulated Powder Quality", FOOD AND BIOPROCESS TECHNOLOGY ; AN INTERNATIONAL JOURNAL, SPRINGER-VERLAG, NEW YORK, vol. 12, no. 1, 20 October 2018 (2018-10-20), pages 122 - 146, XP036665297, ISSN: 1935-5130, [retrieved on 20181020], DOI: 10.1007/S11947-018-2194-2 *
WU CHENG-TIEN ET AL: "Genotoxicity and 28-day oral toxicity studies of a functional food mixture containing maltodextrin, white kidney bean extract, mulberry leaf extract, and niacin-bound chromium complex", REGULATORY TOXICOLOGY AND PHARMACOLOGY, vol. 92, 1 February 2018 (2018-02-01), US, pages 67 - 74, XP055796900, ISSN: 0273-2300, DOI: 10.1016/j.yrtph.2017.11.008 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165856A1 (en) * 2022-03-02 2023-09-07 Société des Produits Nestlé S.A. Use of a composition for managing postprandial glucose response and associated disorders
GR1011012B (en) * 2024-05-21 2025-07-23 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε. Με Το Διακριτικο Τιτλο "Uni-Pharma A.B.E.E.", Berry extract-based cardioprotection composition

Also Published As

Publication number Publication date
TW202139863A (en) 2021-11-01

Similar Documents

Publication Publication Date Title
Alada The haematological effect of
CN102204663B (en) Tomato sauce added with fennel essential oil
WO2021156184A1 (en) New formulation of a plant extract
CN105213261A (en) A kind of black fruit matrimony vine oxidation resistant skin care item
Ayotunde-Ezekiel et al. Effect of partial replacement of fishmeal with Moringa oleifera leaf meal on the haematology, carcass composition and growth performance of Clarias gariepinus (Burchell 1822) fingerlings
CN105995048A (en) Feed for improving muscle quality of carps and preparation method of feed
Alvarado et al. Activity of Lepidium meyenii Walp (purple maca) in immunosuppressed Oryctolagus cuniculus (albino rabbits).
Oragwu Ifeoma et al. Phytochemical and proximate composition of cucumber (Cucumis Sativus) seed oil
Zia-Ul-Haq et al. Mineral contents and antioxidant potential of selected legumes of Pakistan
CN108835636B (en) Hawthorn health food for assisting in reducing blood sugar
KR102364428B1 (en) Cosmetic composition containing fermented grain extract having high antioxidative activity
CN108813156A (en) A kind of small aroma chicken feed additive and the preparation method and application thereof, small aroma chicken feed
Wang et al. Isolation of acidic mucilage from the outer seed coat of shaddock (Citrus grandis Osbeck) and evaluation of its functional properties
AU2013303289B2 (en) Mutant tomatoes and use thereof for preventing weight gain and/or treating obesity-related conditions
Aicha et al. Chemical composition and mineral contents of leaflets, rachis and fruits of Chamaerops humilis L.
CN114504615A (en) Extract composition with liver protecting and enzyme reducing effects
KR101073624B1 (en) Compositions comprising young Phragmites communis leaves or extracts thereof for preventing or improving obesity, or antioxidant activity
Eu-Jin et al. Immune-enhancing effects of Protaetia brevitarsis seulensis larvae extracts on RAW264. 7 macrophages
CN108813155A (en) A kind of feed addictive and the preparation method and application thereof improving immunity of layer chicken, egg feedstuff
CN105878333A (en) Compound protective agent, preservation method and application of bitter melon extracting liquid
KR101773450B1 (en) Anti-inflammatory composition comprising enzymatically modified red ginseng extract as a active component
KR20150127849A (en) Healthy food composition having anti-oxidative activity
KR101441291B1 (en) Cosmetic composition comprising extract of Baby brier and Lespedeza cuneata for whitening and antioxdiant
Popović-Đorđević et al. Bioactive compounds and antioxidant activity of bean-based" cheese" enriched with spices and microgreens
KR20140097718A (en) A health food composition for preventing inflammatory comprising the extracts or fractions of Amaranth as effective component

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21705112

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21705112

Country of ref document: EP

Kind code of ref document: A1